NLRP3 and hemolytic-uremic syndrome: Therefore, our findings provided evidence supporting that the Nlrp3 inflammasome activation induced by Stx2 contributes to the development of HUS, and suggesting that the Nlrp3 inflammasome can be the potential target for HUS therapy.